Distribution and excretion of a phosphorothioate oligonucleotide in rats with experimentally induced renal injury.
The effects of renal injury on the urinary excretion and tissue distribution of a 20-mer phosphorothioate oligonucleotide were investigated in male Sprague-Dawley rats. Renal injury was produced by treating the rats with either 5.0 mg/kg cisplatin or 2.5 mg/kg of a monoclonal antibody (mAb) directed toward Thy1.1. Controls received saline. Three days after cisplatin treatment or 2 days after anti- Thy1.1 treatment, the rats received 10 mg/kg ISIS 3521. Blood was collected at various times to assess the plasma concentrations of ISIS 3521, and rats were killed at various times from 6 to 48 hours after intravenous (i.v.) infusion of oligonucleotide to assess tissue concentrations by capillary gel electrophoresis (CGE). Cisplatin and anti-Thy1.1 antibody produced histologic and biochemical changes consistent with proximal tubular damage and glomerular damage, respectively. Urinary excretion of oligonucleotides was increased 2- to 4-fold of control; however, this amount accounted for only 1% to 2% of dose compared to 0.5% in controls. Proximal tubular damage reduced renal accumulations of ISIS 3521 and other oligonucleotide metabolites, but there were no obvious compensatory increases in concentrations in other organs except for a slight increase in spleen levels of total oligonucleotide. Glomerular damage was not associated with any change in oligonucleotide disposition. Immunohistochemical studies showed no evidence of alterations in the pattern of distribution within the injured kidney. The data suggest that acute renal dysfunction, either renal tubular or glomerular, does not markedly alter the urinary elimination and tissue deposition of a phosphorothioate oligonucleotide.
Masarjian
Lilit
L
Graduate School of Public Health, San Diego State University, San Diego, CA 92182, USA.
de Peyster
Ann
A
Levin
Arthur A
AA
Monteith
David K
DK
D000818:Animals; D007150:Immunohistochemistry; D007678:Kidney Glomerulus / Q000187:drug effects* / Q000293:injuries / Q000473:pathology; D007684:Kidney Tubules / Q000187:drug effects* / Q000293:injuries / Q000473:pathology; D008297:Male; D020319:Oligodeoxyribonucleotides, Antisense / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000652:urine; D009928:Organ Specificity; D051381:Rats; D017207:Rats, Sprague-Dawley; D013873:Thionucleotides / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000652:urine; D013997:Time Factors
D020319:Oligodeoxyribonucleotides, Antisense; D013873:Thionucleotides; C108494:ISIS 3521